Previous 10 | Next 10 |
2023-11-07 16:06:59 ET More on Celldex Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU Biggest stock movers today: Paramount Global, Organigram, Celldex Therapeutics and more Celldex jumps premarket on positive topline results from urticaria...
Celldex Therapeutics, Inc. (NASDAQ: CLDX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.31% on the day to $22.68. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal ...
2023-11-06 07:15:28 ET Related stories: NIO: Fell From Grace And Significantly Underperforming (Rating Downgrade) Organigram Is A Great Stock For Value Investors NIO: Improving Setup (Rating Upgrade) For further details see: Biggest stock movers today: Or...
2023-11-06 07:03:00 ET More on Celldex Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU Wells Fargo starts Celldex at underweight, cites over-optimism for hives drug Seeking Alpha’s Quant Rating on Celldex Historical earnings d...
2023-11-03 16:25:23 ET More on Celldex Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU Wells Fargo starts Celldex at underweight, cites over-optimism for hives drug For further details see: Celldex Therapeutics files for a mixed shelf of...
Celldex Therapeutics Inc. (CLDX) is expected to report $-0.67 for Q3 2023
2023-11-02 17:22:39 ET More on Celldex Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU Wells Fargo starts Celldex at underweight, cites over-optimism for hives drug Seeking Alpha’s Quant Rating on Celldex Historical earnings d...
- Phase 2 CSU enrollment complete; topline data by YE 2023 - - Phase 1b PN data accepted at World Congress on Itch - HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 202...
HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), be...
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 26 th at 1:00 pm ET. A webcast of the presentation will be available ...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...